A massive wave of targeted therapies has turned the life sciences industry on its head in recent years. The acceleration of innovative precision medicines, cell and gene therapies, orphan drugs, and countless other specializations is creating new opportunities for pharmaceutical and biotech companies to customize their approach to treatment. These novel therapies are completely shifting the extensibility of treatments and the way companies perceive patient care. They have also created a monumental swing in the clinical trial materials and supplies market, which is projected to grow at a 6% CAGR and reach a value of approximately $26 billion by 2025.
Companies engaged in clinical manufacturing must continually make rapid yet precise adjustments. To pivot quickly, companies need the right proficiencies and tools. Learn the keys to adapting operations to suit a more targeted approach to development.